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AN ADAPTIVELY WEIGHTED STATISTIC FOR DETECTING
DIFFERENTIAL GENE EXPRESSION WHEN COMBINING
MULTIPLE TRANSCRIPTOMIC STUDIES
By Jia Li and George C. Tseng1
University of Pittsburgh
Global expression analyses using microarray technologies are be-
coming more common in genomic research, therefore, new statisti-
cal challenges associated with combining information from multiple
studies must be addressed. In this paper we will describe our pro-
posal for an adaptively weighted (AW) statistic to combine multi-
ple genomic studies for detecting differentially expressed genes. We
will also present our results from comparisons of our proposed AW
statistic to Fisher’s equally weighted (EW), Tippett’s minimum p-
value (minP) and Pearson’s (PR) statistics. Due to the absence of
a uniformly powerful test, we used a simplified Gaussian scenario to
compare the four methods. Our AW statistic consistently produced
the best or near-best power for a range of alternative hypotheses.
AW-obtained weights also have the additional advantage of filter-
ing discordant biomarkers and providing natural detected gene cate-
gories for further biological investigation. Here we will demonstrate
the superior performance of our proposed AW statistic based on a
mix of power analyses, simulations and applications using data sets
for multi-tissue energy metabolism mouse, multi-lab prostate cancer
and lung cancer.
1. Introduction. Integrating results from multiple biological studies is
now considered commonplace, with significance levels and effect sizes of-
ten used in meta-analyses. Random effects models which models effect sizes
are frequently used to address variation in sampling schemes. Differences
in data structures and statistical hypotheses are common in multiple ap-
plications, making direct combinations of effect sizes difficult or impossi-
ble. It is more feasible to combine the transformed probability integrals
of test statistics (usually p-values), since the procedure is only dependent
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on the significance values of individual tests instead of on underlying data
structures. Fisher’s (1932) well-known method of this type involves the log-
transformation of p-values to Chi-square scores and the equally-weighted
summation: V EW =−∑Kk=1 log(pk), where K studies are combined and pk
is the p-value of study k, 1≤ k ≤K. Assuming independence among stud-
ies and p-values calculated from correct null distributions in each study,
2V EW follows a Chi-square distribution with 2K degrees of freedom under
the null hypothesis. Previously considered other transformations include in-
verse normal [Stouffer et al. (1949)], logit [Lancaster (1961)] and inverse
Chi-square transformation with varying degrees of freedom [George (1977)],
among many others. Although Fisher’s method is not the most uniformly
powerful, it does exhibit good power for a wide range of conditions. It is
also recognized for its asymptotically Bahadur optimal (ABO) character-
istic, with multiple studies having the same effect size for alternative hy-
potheses [Littell and Folks (1971, 1973)]. Different weights or variations of
Fisher’s statistic have also been considered. Good (1955) suggested using
unequal weights for individual studies in which weights are determined by
decisions made by subject experts. More recently, Olkin and Saner (2001)
have proposed a trimmed version of Fisher’s statistic to remove the potential
effects of aberrant extremes. Another well-known method in the category of
combining p-values is Tippett’s (1931) minimum p-value statistic (minP):
V minP =min1≤k≤K pk. Wilkinson (1951) generalized Tippett’s procedure to
a more robust rth smallest p-value, in which V maxP =max1≤k≤K pk (maxP)
is widely used. Note that minP and maxP statistics align with Roy’s (1953)
union–intersection test and Berger’s (1982) intersection–union test, respec-
tively. For comprehensive reviews and comparisons of various meta-analysis
approaches, see Hedges and Olkin (1985) and Cousins (2007).
Microarray supports the examination of the expression of thousands of
genes in parallel. As microarray experiments become more mature and com-
mon, it has become increasingly important to integrate homogeneous exper-
imental data sets from multiple laboratories and experimental techniques.
In contrast to traditional epidemiological or evidence-based medical stud-
ies, the process of monitoring the expression for thousands of genes simul-
taneously presents many challenges to integrative analysis. In the current
biological literature, the term meta-analysis refers to the widespread use of
naive intersection/union operations or vote counting on lists of differentially
expressed genes obtained from individual studies using certain criteria—for
instance, False Discovery Rate≤ 0.05 [Borovecki et al. (2005); Cardoso et al.
(2007); Pirooznia, Nagarajan and Deng (2007); Segal et al. (2004), among
many others]. Intersections are too conservative and unions insufficiently
conservative, especially as the value of K increases.
More sophisticated meta-analysis methods can be divided into two tradi-
tions, the first being the use of a summary statistic—that is, a combination
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of statistics from individual studies for each gene being considered, adjusted
for multiple comparisons. In many situations, this type of method is an
extension of traditional meta-analysis methods. For example, Rhodes et al.
(2002), who were the first to apply Fisher’s method to microarray data, later
introduced a weighted average of test statistics from individual tests, with
weights determined by study sample sizes [Ghosh et al. (2003)]. Moreau et
al. (2003) made use of Tippett’s minimum p-value. A more robust statistic is
Wilkinson’s rth smallest p-value, in which maximum p-value can be applied
to the meta-analysis of microarray studies. Owen (2009) reintroduced Pear-
son’s (1934) method and applied it to the AGEMAP project. He defined
a test statistic as the maximum of Fisher’s combination of left-sided and
right-sided p-values. All of these methods combine statistical significance.
Note that when no gene effect exists, the p-value is uniformly distributed.
Accordingly, combining the significance of independent tests is sometimes
called omnibus or nonparametric. When studies have similar design and
measure the outcomes in similar ways, combining effect sizes is usually pre-
ferred to combining significance. Choi et al. (2003) used weighted estimate
for individual genes based on the random effects model (REM) under Gaus-
sian assumptions, and discussed the details of a Bayesian formulation for the
REM model. Hu, Greenwood and Beyene (2005) developed a quality mea-
sure for each gene in individual studies, incorporating a quality index as a
weight in the REM model. Hong et al. (2006) proposed a robust rank-based
approach for meta-analysis. Choi et al. (2007) introduced a latent variable
approach.
The second meta-analysis tradition is Bayesian—for example, Choi et
al.’s (2003) Bayesian version for REM, which models the effect sizes. Similar
Bayesian hierarchical models have been suggested by Tseng et al. (2001) and
Conlon, Song and Liu (2006) for incorporating different levels of replicates
information in cDNA microarray experiments. Conlon, Song and Liu (2007)
refer to these models as Bayesian probability integration (PI) models, and
have introduced a Bayesian standardized expression integration (SEI) model.
Instead of modeling study specific means separately (PI model), SEI models
them as samples from a normal distribution, thus producing overall mean
and inter-study variation. Shen, Ghosh and Chinnaiyan (2004) and Choi et
al. (2007) used a Bayesian mixture model to rescale the individual data set
and then combined all data sets for an ordinary gene expression analysis.
The structure for the rest of this paper is as follows: in Section 2 we de-
scribe two complementary hypothesis settings for detecting study-invariant
and study-specific biomarkers: HSA and HSB . In Section 3 we present our
proposal for an adaptively weighted (AW) statistic for meta-analyses of ge-
nomic studies, including detailed descriptions of the AW statistic algorithm
and a permutation test for combining multiple studies. In Section 4 we dis-
cuss a simulation test of our proposed method, using data sets from studies
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of a multi-tissue energy metabolism mouse model, prostate cancer and lung
cancer; we then compare our results with those produced by three other
commonly used methods. In Section 5 we demonstrate the admissibility and
power of our proposed AW test under a Gaussian assumption, and in Sec-
tion 6 we summarize its statistical advantages and limitations.
2. Two major complementary hypothesis settings. To our knowledge, no
comprehensive evaluations for the above-described meta-analysis methods
have been performed, primarily due to a lack of rigorous formulation of sta-
tistical hypotheses. Here we will consider a meta-analysis of D1,D2, . . . ,DK
gene expression profiles studies. xkgs is the gene expression intensity of gene
g and sample s in study k, with samples s= 1, . . . , nk belonging to a control
group (e.g., normal samples) and s = nk + 1, . . . , nk +mk belonging to the
diseased group (e.g., cancer samples). Normally a null hypothesis for each
gene g is considered as
H0 : θg1 = · · ·= θgK = 0,
where θgk represents the gene effect of gene g and study k. Building on
Birnbaum’s (1954) work, the complementary hypothesis settings (HSA and
HSB) are dependent upon the nature of the experiment in which the gene
effects (θgk) are obtained:
HSA :{H0 versus HA : θgk 6= 0,∀1≤ k ≤K},
HSB :{H0 versus HB : at least one θgk 6= 0,1≤ k ≤K}.
It is possible to use different methods to explicitly or implicitly consider
different subsets or variations of the two alternative hypotheses:
HSA1 :{H0 versus HA1 : θg = θg1 = · · ·= θgK 6= 0},
HSA2 :{H0 versus HA2 : θg 6= 0, θgk ∼N(θg, τ2)},
HSBh :{H0 versus HBh :
K∑
k=1
I(θgk 6= 0) = h (1≤ h≤K)}
[I(·) is an indicator function that
equals 1 when statement true and 0 otherwise],
HSBh′ :
{
H0 versus HBh′ :
K∑
k=1
I(θgk 6= 0) = h
and θgk = θg if θgk 6= 0 (1≤ h≤K)
}
.
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Without danger of confusion, here we will use HA notation to denote the
parameter space of the corresponding alternative hypothesis. It is clearly
seen that HA ⊂HB . However, they represent two families of complementary
interpretations in applications. Under HA, gene g is identified only when it
is differentially expressed in all studies. Under HB , gene g is selected only
if it is differentially expressed in one or more studies. Note that HA1 ⊂HA,
representing an equal fixed effect model. HA2 represents a random effects
model for a similar HA purpose, while HA2 6⊆HA in general. Note also that
HB =
⋃
1≤h≤KHBh, HBh′ ⊂HBh (1≤ h≤K) and HBK ′ =HA1.
From a biological standpoint, experimental design and meta-analysis ob-
jectives determine biomarker lists of interest. To illustrate this idea, we will
use three sets of microarray studies for meta-analyses. The first set consists
of two mouse genotypes, wild type (VLCAD +/+) and VLCAD deficient
(VLCAD −/−), with four mice in each genotype group (VLCAD is as-
sociated with a childhood metabolism disorder). Brown fat, liver and heart
tissue samples were collected from each of the eight individual mice and used
for microarray experiments designed to study global expression changes in
the knock-out of VLCAD (Table 1, left). Given the experimental design, a
biomarker list of interest might consist of those genes that are consistently
expressed in all tissue samples from both wild type and VLCAD-deficient
mice. This type of tissue-invariant (or study-invariant) biomarker list can
be loosely defined as GA, with analysis based on the alternative hypoth-
esis family of HA. However, it is reasonable to assume that tissue-specific
physiology triggers tissue-dependent responses, with pools of differentially
expressed genes being confounded to the tissues in question. Such a hy-
pothesis would focus on signature genes that are differentially expressed in
subsets of one or more tissues—an analysis that corresponds to theHB alter-
native hypothesis family. Hereafter we will use the term GB when addressing
such tissue-specific or study-specific biomarker lists. In the second study set,
microarray comparisons of normal versus prostate tumor tissues were per-
formed by three different research teams: Dhanasekaran et al. (2001), Luo
et al. (2001) and Welsh et al. (2001) (Table 1). The GA study-invariant
biomarker list is clearly of greater biological interest in this situation, since
many of the GB study-specific biomarkers represent experimental and tech-
nical discrepancies between studies, possibly due to sample population het-
erogeneity, gene matching errors or differences in experimental protocols.
Further investigation of study-specific biomarkers may provide technical in-
sights to experimental design features without providing biological insights
to the disease of interest. The third set of microarray studies [Bhattachar-
jee et al. (2001); Beer et al. (2002); Garber et al. (2001)] included analyses
of lung cancer samples and a comparison of normal versus adenocarcinoma
samples. Table 1C shows the pair-wise integrative correlation coefficients
[Parmigiani et al. (2004)] in each of the three examples. A review of past
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Table 1
Three sets of microarray studies for meta-analyses. (BF—brown fat; Liv—liver; Ht—heart; WT—wild type (VLCAD +/+);
VLCAD—VLCAD −/−; N—normal; T—tumor; AC—adenocarcinomas)
(A) Mouse energy metabolism Prostate cancer studies Lung cancer studies
BF Liv Ht Dhan Luo Wels Bhat Beer Garb
WT 4 4 3 N 19 9 9 N 17 10 5
VLCAD 4 4 4 T 14 16 25 AC 134 86 39
(B)
HSA Of biological interest Of biological interest Of biological interest
HSB Of biological interest Of less biological interest Of less biological interest
but of more technical interest but of more technical interest
(C)
BF 1 0.06 0.04 Dhan 1 0.05 0.09 Bhat 1 0.33 0.22
Liv 0.06 1 0.03 Luo 0.05 1 0.09 Beer 0.33 1 0.15
Ht 0.04 0.03 1 Wels 0.09 0.09 1 Garb 0.22 0.15 1
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Table 2
Meta-analysis methods, corresponding hypothesis settings and targeted types of
biomarker list
Alternative Targeted
Methods Abbreviation hypothesis biomarker list
Fisher [equally weighted sum of EW HB GB
log(p-values)]
Tippett (minimum p-value) minP HB GB
Pearson (maximum of Fisher’s left- PR HB GB
sided and right-sided score)
Li and Tseng [adaptively weighted AW HB GB
sum of log(p-values)]
Wilkinson (maximum p-value) maxP HA GA
Choi (2003); Shen (2004); Choi (2007) REM HA2 GA
(random effects model)
Conlon (2006) (PI Bayesian approach) PI NA GA
Conlon (2007) (SEI Bayesian approach) SEI NA GA
meta-analyses reveals that lung cancer studies generally have larger samples,
greater homogeneity and better data quality than prostate cancer studies,
especially in terms of biomarker detection and classification analysis.
Table 2 presents a list of commonly used meta-analysis methods for mi-
croarray studies, their corresponding alternative hypotheses and targeted
biomarkers. While both Bayesian SEI and PI methods tend to detect GA-
type biomarkers across studies, the Bayesian concept does not involve hy-
pothesis testing. Note that different approaches have distinctly different ad-
vantages and disadvantages in terms of parameter space subsets in alterna-
tive hypotheses, even though two methods may be designed for the same
hypothesis. For example, to detect GA genes, PI performs better than SEI
for genes that have a high mean effect in one study but low mean effect in
another. According to Laughin (2004), maxP is generally under-powered,
but performs well when all θgk values are nonzero and roughly the same.
As we will show in Section 5, EW, minP, PR and AW are all admissible for
detecting GB genes. For HBh, EW tends to be more powerful when h is large
and closer to K. Little and Folks proved that EW is asymptotically ABO
when detecting GA-type genes under under HBK ′ (i.e., HA1), even though
the EW statistic is targeted toward general HB . In contrast, minP is more
powerful in detecting genes under HBh when h is small.
From this point forward, our focus will be on the HB alternative hypoth-
esis. In the following section we will describe our proposal for an adaptively
weighted statistic (AW), and, in Section 5, we will demonstrate its robust-
ness and near-optimal power for alternative hypotheses at either extreme
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(i.e., when h is close to K or close to 1 in HBh′). We will also give exam-
ples of situations in which AW outperforms EW and minP in intermediate
scenarios. AW is capable of distinguishing GA and GB\GA genes in a man-
ner that indicates in which study or studies individual biomarkers are dif-
ferentially expressed—information considered useful for post-meta-analysis
investigations.
3. Adaptively-weighted statistic. When integrating multiple genomic stud-
ies, expression of some important biomarkers may be altered in a study-
specific manner (consider HB). To uncover altered gene expression patterns
across studies, we start with the following weighted statistic:
Ug(wg) =−
K∑
k=1
wgk log(pgk),(3.1)
where pgk is the p-value of gene g in study k, wk is the weight assigned
to the kth study and wg = (wg1, . . . ,wgK). Under the null hypothesis that
θgk = 0 ∀k, the p-value of the observed weighted statistic, pU(ug(wg)), can
be obtained for a given gene g and weight wg (see below for detailed permu-
tation algorithm to calculate the p-value). The adaptively-weighted statistic
is defined as the minimal p-value among all possible weights:
V AWg = min
wg∈W
pU(ug(wg)),(3.2)
where ug(w) is the observed statistic for Ug(w), and W is a prespecified
search space. Our choice of search space in this paper is W = {w | wi ∈
{0,1}}, which results in an affordable computation of O(2K − 1) based on
the norm of K ≤ 10 in a microarray meta-analysis.
The resulting weight reflects a natural biological interpretation of whether
or not a study contributes to the statistical significance of a gene. Note that
the AW statistic is inadequate for traditional meta-analysis in epidemiolog-
ical or evidence-based medicine research. The AW selection procedure will
introduce selection bias toward studies with concordant significant effects.
However, integrative analysis of genomic studies represents a different situ-
ation: usually the primary goal is to screen and identify the most probable
gene markers, given data meant to facilitate future investigation. As we will
show in Section 4, the weight vector, w∗g = argminwg∈W pU (ug(wg)), actually
serves as a convenient basis for gene categorization in follow-up biological
interpretations and explorations.
Below we illustrate the detailed procedure for AW when applied to com-
bined genomic studies. If assuming pgk ∼Unif[0,1] under the null hypoth-
esis, Ug(wg)∼Gamma(
∑K
k=1wgk,1) and inference of the AW statistic can
be performed on this basis. Such a uniform p-value assumption is, however,
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usually not true in real applications. Alternatively, a permutation test is
performed below to assess the statistical significance and the false discovery
rate (FDR) is controlled at 5%. For the applications in Section 4, the EW,
minP, maxP and PR methods are performed using a similar permutation
test.
I. Study-wise p-value calculation before meta-analysis:
(1) Compute the penalized t-statistics, tgk, for gene g and study k
[Efron et al. (2001); Tusher, Tibshirani and Chu (2001)].
(2) Permute group labels in each study for B times, and similarly cal-
culate the permuted statistics, t
(b)
gk , where 1≤ g ≤G,1≤ k ≤K,1≤
b≤B.
(3) Estimate the p-value of tgk as pgk = (
∑B
b=1
∑G
g′=1 I(t
(b)
g′k ∈R(tgk)))/
(B ·G), where R(tgk) is the rejection region given the threshold tgk.
Similarly, given t
(b)
gk , compute p
(b)
gk = (
∑B
b′=1
∑G
g′=1 I(t
(b′)
g′k ∈R(t
(b)
gk )))/
(B ·G).
II. Calculate AW statistic:
(1) Given a weight wg = (wg1, . . . ,wgK), the weighted statistic is de-
fined as ug(wg) =−
∑K
k=1wgk log(pgk) for gene g. Define u
(b)
g (wg) =
−∑Kk=1wgk log(p(b)gk ).
(2) Estimate the p-value of the observed ug(wg) as
pU (ug(wg)) =
∑B
b=1
∑G
g′=1 I{u(b)g′ (wg)≥ ug(wg)}
B ·G .
Similarly compute
pU (u
(b)
g (wg)) =
∑B
b′=1
∑G
g′=1 I{u(b
′)
g′ (wg)≥ u
(b)
g (wg)}
B ·G .
(3) Based on II(1) and II(2), calculate the optimal weight as
w∗g = arg min
wg∈W
pU (ug(wg))
and, similarly,
w(b)∗g = arg min
wg∈W
pU(u
(b)
g (wg)).
Define the AW statistic Vg as the p-value of the adaptively weighted
statistic: Vg = pU (ug(w
∗
g)). Similarly, V
(b)
g = pU (u
(b)
g (w
(b)∗
g )).
III. Assess p-values and q-values of the AW statistic—Vg :
(1) The p-value of Vg is calculated as
pV (Vg) =
∑B
b=1
∑G
g′=1 I{V (b)g′ ≤ Vg}
B ·G .
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(2) Estimate π0, the proportion of null genes, as
π̂0 =
∑G
g=1 I{pV (Vg) ∈A}
G · ℓ(A)
[Storey (2002)]. Normally we choose A= [0.5,1] and ℓ(A) = 0.5.
(3) Estimate the q-value for each gene as
q(Vg) =
π̂0
∑B
b=1
∑G
g′=1 I{V (b)g′ ≤ Vg}
B
∑G
g′=1 I{Vg′ ≤ Vg}
.
The detected gene list is GAW = {g : qV (Vg)≤ 0.05}.
IV. Distinguish concordant and discordant genes (recommended): Split the
detected gene list GAW into concordant and discordant gene lists. By
controlling the false discovery rate (FDR) at 5%, detected genes with
concordant regulation direction across contributing studies are denoted
as GAWconcordant = {g : q(Vg)≤ 0.05 and |
∑K
k=1 sgn(tgk) ·w∗gk|=
∑K
k=1w
∗
gk},
where sgn(·) is the sign function that takes value 1 when positive and −1
when negative. The discordant gene list isGAWdiscordant =G
AW\GAWconcordant .
Remarks.
1. For the application of EW and the minP, maxP and PR method, steps
II(1)–II(3) can be skipped. Alternatively, the test statistics are modi-
fied as Vg =−
∑K
k=1 log(pgk) for EW; Vg =min1≤k≤K pgk for minP; Vg =
max1≤k≤K pgk for maxP and Vg =max(−
∑K
k=1 log(p˜gk),−
∑K
k=1 log(1−
p˜gk)) for PR, where p˜gk is the one-sided p-value for gene g in study k.
2. The I–III sequence provides an algorithm for a general framework. Both
statistics tgk and rejection region R(tgk) can be replaced, depending on
the experimental design and hypothesis. For example, the F -statistic can
be used when multiple groups of samples are available in each study under
consideration.
3. When conducting comparisons of two groups and applying the moder-
ated t-statistic, genes detected under the general framework (the I–III se-
quence) may contain discordant genes—for instance, a gene up-regulated
in one study and down-regulated in another; the addition of step IV pro-
vides further filtering. In some applications, a researcher may want to
scrutinize the discordant gene list to verify whether the discordance re-
flects actual biological discrepancy across studies (e.g., different tissues
or patient populations) or artificial errors (e.g., mistakes in gene annota-
tion). For EW and minP there is no direct criterion for a clear split of
concordant and discordant genes. After revisiting the PR method for the
AGEMAP project, Owen found that it is sensitive to consistent left- or
right-sided departures. The PR method is still easily dominated by one or
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two exceptionally significant p-values, and does not identify which stud-
ies are significant in distinguishing between concordant versus discordant
patterns (see first two examples in Table 6).
4. Several forms of penalized or moderated t-statistics have been proposed
and shown to outperform traditional t-statistics [Efron et al. (2001);
Tusher, Tibshirani and Chu (2001); Smyth (2004)]. For our algorithm we
choose the penalized t-statistics used in Efron et al. (2001) and Tusher,
Tibshirani and Chu (2001). The fudge parameter s0 is chosen to be the
median variability estimator in the genome.
4. Applications.
4.1. Simulation study. We conducted a simulation study for combining
four data sets to compare the performance among our proposed AW test,
Fisher’s EW test, Tippett’s minP method, Wilkinson’s maxP method and
Pearson’s statistic (PR). For each data set, we simulated five normal samples
from a standard normal distribution and five case samples from N(θ,1). A
total of g1 genes (category I) were differentially expressed across all four
data sets; g2 = 400 − g1 genes were differentially expressed in the fourth
data set only (category II); and 1600 genes were considered null. Genes are
called significant by controlling FDR at 5% for each method. Each simulation
scenario was repeated 1000 times.
Summaries of the resulting FDR and average number of genes identified in
each category under three different scenarios appear in the following tables:
0 category I and 400 category II genes in Table 4; 200 category I and 200
category II genes in Table 5; 400 category I and 0 category II genes in
Table 3. The results are consistent with the power calculation discussed
in Section 5.1. In Table 3, minP is much more powerful than EW. When
θ = 2, minP correctly detects an average of 41.6 genes and EW detects only
Table 3
Evaluation of AW, EW, minP, maxP and PR methods by simulations in the
first scenario (I. 0 common DE genes; II. 400 4th-data set-specific DE genes;
Null. 1600 random noise genes). Average number of genes detected in each
category and the average FDR are shown under different effect size θ
θ = 2.0 θ = 2.5
Methods I II Null FDR (s.e.) I II Null FDR (s.e.)
AW 0.0 32.1 1.9 4.8% (0.002) 0.0 137.1 7.5 4.9% (0.001)
EW 0.0 7.6 0.4 4.1% (0.003) 0.0 43.1 2.0 4.2% (0.002)
minP 0.0 41.6 2.4 5.0% (0.002) 0.0 163.0 8.7 4.9% (0.001)
maxP 0.0 0.2 0.1 25.5% (0.013) 0.0 0.2 0.1 25.5% (0.013)
PR 0.0 3.2 0.1 3.7% (0.004) 0.0 15.2 0.4 2.2% (0.002)
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Table 4
Evaluation of AW, EW, minP, maxP and PR methods by simulations in the second
scenario (I. 200 common DE genes; II. 200 4th-data set-specific DE genes; Null.
1600 random noise genes). Average number of genes detected in each category and
the average FDR are shown under different effect size θ
θ = 1.5 θ = 2.0
Methods I II Null FDR (s.e.) I II Null FDR (s.e.)
AW 169.1 24.3 10.1 4.9% (0.0005) 198.7 59.4 13.4 4.9% (0.0004)
EW 188.4 16.9 8.5 4.0% (0.0004) 199.8 35.4 9.5 3.9% (0.0004)
minP 25.4 6.9 1.9 5.0% (0.0016) 144.0 54.7 10.3 4.9% (0.0005)
maxP 168.3 3.7 8.4 4.6% (0.0005) 195.7 4.4 9.8 4.7% (0.0005)
PR 178.7 9.4 3.8 2.0% (0.0003) 199.3 21.3 4.3 1.9% (0.0003)
7.6 genes. AW detects 32.1 genes, considerably close to minP. Similarly,
in Table 5, EW (386.8 genes are detected when θ = 1.5) is more powerful
than minP (121.3 genes detected) and AW (359.3 genes detected) is close to
EW in performance. Overall, AW performance was stable in these extreme
situations. We note most methods show FDR close to 5%, although maxP
loses so much power at scenario 1 that FDR is inflated and the PR method
appears slightly conservative.
4.2. Energy metabolism in mouse model. An energy metabolism disorder
in children is associated with very longchain acyl-coenzyme A dehydroge-
nase (VLCAD) deficiencies. In an ongoing unpublished project, two geno-
types of the mouse model—wild type (VLCAD +/+) and VLCAD-deficient
(VLCAD −/−)—were studied for three types of tissues (brown fat, liver
and heart) with 4 mice in each genotype group. Microarray experiments
were applied separately to study the expression changes across genotypes.
Table 5
Evaluation of AW, EW, minP, maxP and PR methods by simulations in the third
scenario (I. 400 common DE genes; II. 0 4th-data set-specific DE genes; Null. 1600
random noise genes). Average number of genes detected in each category and the average
FDR are shown under different effect size θ
θ = 1.5 θ = 2.0
Methods I II Null FDR (s.e.) I II Null FDR (s.e.)
AW 359.3 0.0 18.6 4.9% (0.0004) 398.5 0.0 20.4 4.8% (0.0004)
EW 386.8 0.0 15.9 4.0% (0.0003) 399.8 0.0 16.1 3.9% (0.0003)
minP 121.3 0.0 6.3 4.8% (0.0007) 329.5 0.0 16.8 4.8% (0.0004)
maxP 357.5 0.0 19.0 5.0% (0.0004) 394.9 0.0 21.3 5.1% (0.0004)
PR 373.9 0.0 7.5 2.0% (0.0002) 399.4 0.0 7.8 1.9% (0.0002)
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Table 6
Five genes from the mouse energy metabolism data. Moderated t-statistics and p-values for individual studies are listed. w∗ represents
AW-obtained weight. AW2 represents AW concordant method
Moderated t-statistic (p-value) Is it detected (q(V )≤ 5%)?
Gene Brown fat Liver Heart EW minP PR AW AW2 Concordant?
1423407 a at 2.2 1.7 −3.7
(0.0027) (0.0027) (0.0014)
√ × √ √ × no
w∗ 1 1 1
1418429 at 3.6 1.1 −3.2
(0.0003) (0.067) (0.002)
√ × √ √ × no
w∗ 1 0 1
1449015 at 0.4 −3.3 −1.8
(0.46) (0.0009) (0.011)
√ × √ √ √ yes
w∗ 0 1 1
1416415 a at −0.8 2.2 2.6
(0.15) (0.0026) (0.0023)
√ × √ √ √ yes
w∗ 0 1 1
1415727 at −1.5 −1.6 −3.5
(0.018) (0.014) (0.0008)
√ × √ √ √ yes
w∗ 1 1 1
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Fig. 1. Heatmaps of gene expressions for differentially expressed genes identified by dif-
ferent methods in the mouse energy metabolism data sets.
In this study we tested the hypotheses that tissue-specific physiology trig-
gers tissue-dependent responses, with precise pools of differentially expressed
genes specific to the tissue in question. The purpose of this hypothesis is to
identify signature genes that are significant for tissue subsets—an analysis
that corresponds to HSB .
Due to the low power of maxP, the Figure 1 data are limited to AW, EW,
minP and PR methods. Note that EW, minP and AW are based on the sum-
marization of p-values across studies, and that the methods alone do not dis-
tinguish among discordant genes with difference in expression across studies
(e.g., up-regulated in one study but down-regulated in another). The modi-
ADAPTIVELY WEIGHTED STATISTIC 15
fied algorithm of AW for filtering out discordant genes (Section 3, step IV)
can be implemented in such situations, since it discards all discordant genes
among studies that contribute to the adaptive weight. The modified AW
algorithm is not applicable to EW, minP and PR because those methods do
not provide which studies should be considered for concordance/discordance
evaluations.
Overall, the general AW detects 203 genes [Figure 1(a)]; among these,
28 genes were conflicting in terms of up- or down-regulations—for example,
Figure 1(b) shows the detection of 175 genes. Adaptive-weights serve as
a natural grouping process for identified genes: 55 genes with weights of
(1,1,1) are differentially expressed in all three tissue types [Figure 1(b)],
and 27 with weights of (0,1,1) were differentially expressed in liver and
heart tissues, but not in brown fat. The number of detected genes related
to heart tissue [(1,1,1), (1,0,1), (0,1,1) and (0,0,1) in Figure 1(b)] is much
higher than that related to brown fat or liver tissues, representing increase
impact of VLCAD deletion in heart metabolism activities. According to the
EW results shown in Figure 1(c), that method detected more genes (329)
than our proposed AW method. However, the identified gene list is difficult
to interpret and investigate, even after reordering by hierarchical clustering.
In this application minP appears to be much less powerful.
To illustrate AW performance in terms of genes that consistently regu-
late in the same direction across data sets, details for five genes are pre-
sented in Table 6. Four of the five methods identified the five example genes
as differentially expressed (the exception was minP). The first two genes
(1423407 a at and 1418429 at) clearly indicate discordant regulation with
opposite moderated t-statistics between brown fat and heart. Even though
Pearson’s method (PR) was specifically designed to detect concordant genes,
it failed to achieve this goal in this particular situation. In contrast, our pro-
posed AW method uses a post-hoc approach (Section 3, step IV) to filter out
discordant genes. Such a post-hoc procedure is not feasible for EW, minP
or PR without indicating which studies are differentially expressed. For ex-
ample, in 1449015 at and 1416415 a at, the AW method with concordance
filtering will still identify them as concordant DE genes, even though regu-
lation of the nonsignificant study (brown fat) contradicts the two significant
studies. The difference between AW and the natural tendency of biologists
to pick studies based on p-values obtained from individual analysis is illus-
trated by the fifth gene, 1415727 at, which produces moderate signals for
brown fat and liver tissue and a very strong signal for heart tissue, to the
degree that it can easily be ignored for brown fat and liver following adjust-
ment for multiple comparisons. It is, in general, difficult to decide whether
it is a (0,0,1)- or (1,1,1)-type of gene. The fact that this gene is moderately
significant in two studies and very significant in a third study enabled AW
to determine that combining results across all three studies gives the best
statistical significance and it should be a (1,1,1)-type of gene.
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4.3. Prostate cancer and lung cancer studies. We applied the AW, EW,
minP and PR methods to three sets of prostate cancer data and three sets
of lung cancer data (Table 1). Some of the studies were performed by cDNA
technology [Dhanasekaran et al. (2001), Luo et al. (2001) and Garber et
al. (2001)] while others used Affymetrix oligo-based technology [Welsh et
al. (2001), Bhattacharjee et al. (2001) and Beer et al. (2002)]. Data set
probes were matched according to their Entrez IDs; the intensities of mul-
tiple probes matching the same ID were averaged. For the prostate cancer
data set, comparisons were made between clinically localized cancer and
benign tissues. For the lung cancer data set we compared tissues from ade-
nocarcinoma patients with those from healthy donors.
The results shown in Figures 2 and 3 reflect characteristics that are simi-
lar to those discussed in the above mouse example. With an exception, minP
did not perform as poorly as it did in Section 4.1. Compared to the other
methods, our proposed AW method identified much clearer patterns. Of the
722 genes in Figure 2(a), 618 genes show consistent regulation across stud-
ies [Figure 2(b)]. Approximately 14% of the identified genes were discordant
across studies. Possible causes of discordant genes may include mistaken gene
annotations in old array platforms [Dai et al. (2005)], differential probe ef-
ficiencies, heterogeneous sample populations across studies and nonspecific
cross hybridizations. According to our findings, only moderately concordant
information existed across the three prostate cancer studies, probably be-
cause (a) their sample sizes were small, or (b) they entailed in-house cDNA
arrays or commercial products that were still in the early stages of develop-
ment. Of the 618 concordant AW-detected genes, 130 genes (21%) were con-
sistent (1,1,1)-type biomarkers and 205 genes (33.2%) were specific to one
study only: 55 (1,0,0)-type biomarkers, 70 of the (0,1,0) type, and 80 of the
(0,0,1) type. The EW, minP and PR methods all detected slightly greater
numbers of biomarkers than the AW method (924, 745 and 882, resp.).
However, in each case the detected biomarkers were difficult to interpret
and follow up, and all three methods presented challenges in terms of guar-
anteeing the detection of concordant genes only. In summary, our findings
suggest that results from individual microarray studies require careful inter-
pretation, and that integrative analyses are appropriate as a validation tool.
Similar patterns and results were obtained when the four methods were
applied to lung cancer studies (Figure 3). The AW method detected 366
genes, with 349 confirmed as concordant (only 4.6% are discordant compared
to 14.4% in prostate cancer). Among the 349 concordant biomarkers, 99 were
type (1,1,1) (28.4% compared to 21% in prostate cancer) and 96 were single
study specific (27.5% compared to 33.2% in prostate cancer): 7 type (1,0,0),
51 type (0,1,0) and 38 type (0,0,1). Overall, our lung cancer studies had
more biomarkers that were consistent in terms of concordant up-regulation
and down-regulation patterns, and fewer single study-specific biomarkers.
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Fig. 2. Heatmaps of gene expression intensities for differentially expressed genes identi-
fied by different methods in the prostate cancer data sets.
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Fig. 3. Heatmaps of gene expression intensities for differentially expressed genes identi-
fied by different methods in the lung cancer data sets.
These results match those from previous reports showing better consistency
among lung cancer studies compared to prostate cancer studies, possibly
due to larger sample sizes, better gene annotations, more specific disease
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subtype comparisons and better array quality. For example, Bhattacharjee
and Beer used Affymetrix platforms, while Garber’s data were generated
from the lab of Pat Brown, the inventor of cDNA arrays.
5. Power and admissibility. In this section we drop the subscript g for
genes and assume independence among studies when comparing five test
statistics (EW, AW, minP, maxP and PR) for HB at the univariate level.
The maxP statistic is included for demonstration purposes although it is not
targeted to HB . To date, no best method for combining multiples studies has
been identified, therefore, choosing a combined statistic must reflect specific
biological purposes. Birnbaum (1954, 1955) established general conditions
for evaluating combined methods, including monotonicity and admissibility.
To compare several combined test procedures, he considered a one-sample
test of the mean of a Gaussian distribution with known variance. We will
use a similar two-sample test of the means of two Gaussian distributions
with known variance:
Zk =
X2k −X1k
σk
√
1/nk1 + 1/nk2
, k = 1,2, . . . ,K,(5.1)
where X1k = (1/nk1) ·
∑nk1
s=1Xks, X2k = (1/nk2) ·
∑nk1+nk2
s=nk1+1
Xks, Xks ∼N(0,
σ2k) when 1≤ s≤ nk1 and Xks ∼N(θk, σ2k) when nk1+1≤ s≤ nk1+nk2. We
will use the two-sided p-values Pk =Pr(|Z| ≥ |zk||θk = 0) for study k, where
Z is the standard normal distribution, to examine the acceptance regions of
the various combined test procedures. The simplified framework is the focus
for the discussion in the Appendix of admissibility and power comparisons
of the five statistics. It is shown there that AW, EW, PR and minP are all
admissible, but maxP is not.
5.1. Power comparison of EW, AW, minP, maxP and PR under HBh′ .
Denote by Θ0 = {θ1 = · · · = θK = 0} and ΘA = {at least one θk 6= 0} (i.e.,
HB) the null and alternative hypothesis. Letting β
AW(θ;α) be the power of
a test controlled at level α for the OW statistic given θ ∈ΘA, we have
βAW(θ;α) = Pr(V AW ≤CAWα |θ) = 1−
∫
ΩAW
K∏
k=1
p(Pk|θ)dP1 · · · dPK ,(5.2)
where CAWα is the solution of v to the equation P (V
AW ≤ v|Θ0) = α, ΩAW =⋂2K−1
j=1 {p(u(wj)) > CAWα } =
⋂2K−1
j=1 {U(wj) < F−1Gamma(∑Kk=1wjk ,1)(1 − C
AW
α )}
and F−1Gamma(α,β) is the inverse CDF of a Gamma distribution with param-
eters α and β, wj = (wj1, . . . ,wjK), wjk ∈ {0,1}, k = 1, . . . ,K, and enumer-
ation index j exhausts all different weight vector possibilities such that∑K
k=1wjk ≥ 1. If the null hypothesis is true, it is generally accepted that
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the individual Pk value is uniformly distributed on [0,1]. The density of the
p-value under alternative law is expressed as
p(P |θ) = p(x|θ)
p(x|0)
∣∣∣∣
x=g(P )
(0≤ P ≤ 1),(5.3)
where x= g(P ) indicates the solution of P =
∫ 1
x f(x|0)dx [Pearson (1938)].
Similarly, the power for EW and minP can be calculated by βEW(θ;α) =∫
ΩEW
∏K
k=1 p(Pk|θ)dP1 · · · dPK , βminP(θ;α) = 1− [
∫ 1
CminPα
p(P | θ)dP ]K and
βmaxP(θ;α) = [
∫ CmaxPα
α p(P | θ)dP ]K , where ΩEW = {−
∑K
k=1 log pk ≥ CEWα },
CEWα = F
−1
Gamma(K,1)(1−α), CminPα = F−1Beta(1,K)(α) = 1−(1−α)1/K , CmaxPα =
α1/K .
In our simplified setting, the Z test in (3) is used for power calculations,
hence, the density of Pk is
p(Pk|θk) = 1
2
exp
{
ck
2
[2Φ−1(1−Pk/2)− ck]
}
(5.4)
+
1
2
exp
{
−ck
2
[2Φ−1(1− Pk/2) + ck]
}
,
where ck =
θk
σk
√
1/nk1+1/nk2
, k = 1, . . . ,K. We consider nk1 = nk2 = 5 and
σk = 1 so that the effect size is represented by θk and power is evaluated
with varying effect sizes.
The graphs in Figure 4 reflect a situation in which K = 10 for simplified
alternative hypothesis HBh′ (1 ≤ h ≤K). Studies with nonzero effect sizes
share a common effect size θ. Power curves under θ ∈ {1.2,1.4} and varying
values of h are displayed. Due to the difficulty of achieving an exact power
calculation for K = 10, we performed 10,000 simulations to generate power
curves. EW and AW are calculated for one-sided p-values for the purpose of
comparability with PR, maxP, minP. In application, it is unlikely that the
signs of effect will be known, therefore, two-sided p-values for maxP, minP,
EW and AW are preferred. As expected, the figure shows that minP is more
powerful than EW when h is small, and EW is more powerful than minP
when h is large. On the other hand, AW performs stably and comparably to
the best method in situations involving the two extremes. The performance
of maxP further confirms Loughin’s conclusion that it has very low power
unless h=K.
6. Discussion. In this paper we described our proposal for an adaptively
weighted (AW) statistic for combining multiple studies, and reported our
findings after applying it to two sets of combined microarray studies. Ac-
knowledging that meta-analysis methods depend heavily on the biological
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Fig. 4. Power analysis of EW, AW, minP, PR and maxP under HBh′ , 1≤ h≤K. We
compare power curves of the five methods combining K = 10 studies. X axis represents h,
the number of studies that have nonzero effects.
question being investigated, we formulated two statistical hypothesis set-
tings (HSA and HSB) to identify differentially expressed genes considered
significant in either partial or full data sets. Classical EW, minP and our
proposed AW methods were used to analyze HSA.
According to our findings, AW, EW and minP are all admissible in simpli-
fied scenarios. In terms of power analysis, EW was more powerful when all
data sets were significant, while minP was more powerful when only one or
a small number of data sets were significant. As a compromise between EW
and minP, the AW method performed close to the best method in either
extreme alternative hypothesis setting (Figure 5). Simulation results also
confirmed this robust property of AW (Tables 3–5). In applications, AW
had the additional advantage of categorizing differentially expressed genes
by their adaptive weights, thus providing a practical basis for further biolog-
ical exploration. In addition to not detecting discordantly regulated genes,
the modified algorithm in Section 3, step IV, was appealing for the specific
biological purpose of identifying all nondiscordant genes.
In this project we restricted the binary 0,1 adaptive weight search space
for purposes of computational convenience and biological interpretability.
For example, in Figure 1(b) the AW data support an immediate catego-
rization of detected biomarkers, as well as information on similar/dissimilar
differential gene expression between tissue pairs. As shown for the EW data
in Figure 1(c), Fisher’s method generated a large number of nontraceable
biomarkers that were difficult to work with in terms of follow-up analy-
ses. Theoretically, it is possible to extend the 0,1 space to a nonrestricted
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Fig. 5. Acceptance regions of EW, AW, minP, PR and maxP statistic for combining
p-values from two independent studies when testing means of Gaussian distributions with
known variances.
real number (i.e., positive weights that add up to 1). However, such results
generate biomarker lists similar to those generated by the EW method [Fig-
ure 1(c)]. In other words, using nonbinary weights may be slightly superior
statistically, but not biologically.
There are three limitations in addition to possible future extensions for fu-
ture research. First, we assumed that all studies contain an identical matched
gene list with no missing values. In actual practice, separate studies to be
combined usually come from different microarray platforms. Requiring an
identical matched gene list and no missing values will exclude many impor-
tant genes that appear in certain studies but not in others, thus requiring
an extension that allows for missing values. Second, we focused on two-
group comparison in this paper, and made a modification in order to limit
detection to genes with concordant expression changes. To compare more
than two groups, the F -statistic and its variations can be applied; resulting
p-values from F tests can be combined similarly as described for the algo-
rithm in Section 3. However, small p-values across studies do not guarantee
concordant expression patterns. To address this problem, we have developed
a multi-class correlation approach [Lu, Li and Tseng (2010)]. Third, our pro-
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posed method focuses on HSB rather than HSA, which is not the case with
many biological applications. Finally, the AW statistic can be extended from
biomarker detection to gene set enrichment analyses. Note that post-meta-
analysis enriched pathways (gene sets) are thought to be more supportive
of biological interpretations.
While we only considered combining multiple microarray studies in this
paper, the methods we described can easily be extended to combinations
of multiple genomic, epigenomic and/or proteomic studies—for instance,
data sets from SNP arrays, genome arrays, methylation arrays, proteomic
experiments and ChIP-on-chip experiments. Additional extensions and/or
alternative models are required to accommodate biological knowledge and
to address specific questions of interest.
APPENDIX: ADMISSIBILITY
A test is considered admissible if it cannot be uniformly improved by
any other test. No single test has been accepted as the most powerful, even
in the simplified scenarios. Birnbaum expressed a necessary and sufficient
condition (known as Theorem 5.1) for any test to be admissible under this
situation.
Theorem 1 [Birnbaum (1954, 1955)]. Under HB and the test statistic
is in the exponential family [e.g., equation (5.1)], the necessary and suffi-
cient condition for a combined test procedure to be admissible is that the
corresponding acceptance region is convex.
Since the acceptance regions of EW and minP have been identified as
convex, both methods are admissible; maxP is not. When proving that the
PR method is admissible, Owen (2009) clarified Birnbaum’s (1954) mis-
interpretation of the PR method. The acceptance regions of EW, minP,
maxP, AW and PR on the plane of a pair of Z statistics at level 0.05 are
shown in Figure 5. When illustrating the rejection regions of several common
combined tests (including EW and minP), Birnbaum showed a preference
because it appeared to be “fairly sensitive in all directions.” From Figure 5,
it is clear that the PR method prefers effects that show common directions
in two studies, since the rejection regions in the first and third quadrants
are less stringent than the second and fourth quadrants. Note that AW ac-
tually shares positive aspects of both EW and minP methods: generally
more sensitive than minP when parameters from both studies depart from 0
and more sensitive than EW when only one of the parameters departs from
0, and more sensitive than the minP method when parameters from both
studies depart from 0. According to the following corollary, AW is admissible
because the intersection of convex sets is convex, therefore, its acceptance
region is convex.
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Corollary 1. The acceptance region of AW is convex and, thus, AW
is admissible under HB and assumption (5.1).
Proof. Denote by pk = 2(1 − Φ(|zk|)) the two-sided p-value, where
Φ(t) =
∫ t
−∞ φ(t)dt, φ(t) is the density of the standard normal distribu-
tion. First we prove that f(zk) =− log(pk) =− log(1−Φ(|zk|)) +C is con-
vex. f ′′(z) = φ(|z|)
[1−Φ(|z|)]2
{φ(|z|)− |z|[1−Φ(|z|)]} when z 6= 0. It is well known
that the elementary upper bound for 1− Φ(x) is φ(x)/x, for x > 0. Thus,
f ′′(z) > 0 when z 6= 0. Since f(z) is continuous at z = 0, f(z) is convex in
z. Hence, f(z1, z2, . . . , zn) =−
∑n
k=1 log(pk) for any n≥ 1 is convex, because
the sum of convex functions is convex. For the AW statistic, the acceptance
region is {z1, z2, . . . , zK : min1≤k≤K p(u(w))> c}, where p(u(w)) is the right-
sided p-value of U(w):{
z1, z2, . . . , zK : min
0≤k≤K
p(u(w))> c
}
=
⋂
Ik∈{0,1},1≤k≤K
{
z1, z2, . . . , zK : p
(
−
K∑
k=1
log[pIkk ]
)
> c
}
=
⋂
Ik∈{0,1},1≤k≤K
{
z1, z2, . . . , zK :−
K∑
k=1
log[pIkk ]< γj
}
,
j = 1,2, . . . ,2K − 1,
γj is F
−1
Gamma(
∑K
k=1 Ik,1)
(1− c). Thus, the acceptance region of AW is convex
since the intersection of convex sets is also convex. 
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